Sanofi and Regeneron Phase 2 trial of dupilumab shows positive results
The findings were published in the Journal of the American Medical Association (JAMA). Dupilumab, an experimental therapy, inhibits the signaling of the IL-4 and IL-3 cytokines. These cytokines are essential for the T helper 2 (Th2) immune response. The inflammation linked to chronic sinusitis with nasal polyps is believed to be caused by Th2. Dupilumab is still being developed clinically and has not been reviewed by any authority that can guarantee its safety or effectiveness.
Some patients suffering from chronic sinusitis with nasal polyposis who have received various treatments and even surgery to remove the polyps still deal with congestion in the nasal cavity, a lost or decreased sense of smell and pain. Dupilumab may be able to give the patients suffering from chronic sinusitis with nasal polyposis hope to be rid of their symptoms for good.
The Phase 2 study is randomized and double-blind. There are 60 patients in total currently enrolled in the placebo-controlled test group. The trial is being conducted at 13 sites across the United States and Europe.